SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

Core Viewpoint - A class action lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud and unlawful business practices related to the company's reporting of discounts to drug distributors [1][2]. Group 1: Legal Issues - The lawsuit concerns whether Regeneron and its officers engaged in securities fraud or other unlawful business practices [2]. - The U.S. Department of Justice filed a complaint against Regeneron under the False Claims Act, alleging the company failed to report millions in discounts, which inflated the Average Sales Price for its products, leading to increased Medicare reimbursements [3]. Group 2: Financial Impact - Following the DOJ announcement, Regeneron's stock price fell by $31.50, or 3.36$904.70 on April 12, 2024 [4]. - On October 31, 2024, Regeneron reported third quarter 2024 financial results, showing only a 3% increase in U.S. net sales for Eylea HD and Eylea, with Eylea HD sales at $392 million, missing estimates of$415 million to $425 million [5]. - After the financial results were released, Regeneron's stock price dropped by$84.59, or 9.2%, closing at $838.20 on October 31, 2024 [5].